Clinical application of bronchoscopy and bronchoalveolar lavage in the immunocompromised host
- PMID: 8087118
Clinical application of bronchoscopy and bronchoalveolar lavage in the immunocompromised host
Abstract
Pulmonary complications are the most frequent cause of morbidity and mortality in immunocompromised patients. The speed of clinical assessment and the initiation of appropriate therapy is critically related to survival. Fibreoptic bronchoscopy and bronchoalveolar lavage (BAL) had proved useful in making the diagnosis of pulmonary complications in a high proportion of immunocompromised patients, where less invasive techniques, such as blood cultures or sputum induction, have failed to establish a diagnosis. Bronchoscopy and BAL cause little discomfort and low morbidity, and should be performed as early in the disease course as possible, preferably before the onset of respiratory failure.
Similar articles
-
Fibreoptic bronchoscopy and bronchoalveolar lavage in the investigation of the immunocompromised lung.N Z Med J. 1992 Jun 10;105(935):215-7. N Z Med J. 1992. PMID: 1598142
-
Role of bronchoalveolar lavage in children with lung disease.Eur Respir J. 1995 Oct;8(10):1725-30. doi: 10.1183/09031936.95.08101725. Eur Respir J. 1995. PMID: 8586129
-
Fiberoptic bronchoscopy and bronchoalveolar lavage for the evaluation of pulmonary disease in children with primary immunodeficiency and cancer.Pediatr Blood Cancer. 2007 Mar;48(3):324-9. doi: 10.1002/pbc.20784. Pediatr Blood Cancer. 2007. PMID: 16568442
-
Bronchoscopic biopsies and bronchoalveolar lavage.Chest Surg Clin N Am. 1996 May;6(2):205-22. Chest Surg Clin N Am. 1996. PMID: 8724275 Review.
-
Role of bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in immunocompromised patients.Curr Opin Infect Dis. 2014 Aug;27(4):322-8. doi: 10.1097/QCO.0000000000000072. Curr Opin Infect Dis. 2014. PMID: 24977681 Review.
Cited by
-
Determination of Ideal Factors for Early Adoption and Standardization of Metagenomic Next-generation Sequencing for Respiratory System Infections.Curr Pharm Biotechnol. 2024;25(17):2266-2277. doi: 10.2174/0113892010246350231030042340. Curr Pharm Biotechnol. 2024. PMID: 38347797
Publication types
MeSH terms
LinkOut - more resources
Medical